ADMA Biologics Inc - Common Stock (NQ:ADMA)

9.720 -0.210 (-2.11%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Bragar Eagel & Squire, P.C. Is Investigating ADMA Biologics, Napco, and L&W and Encourages Investors to Contact the Firm

October 21, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm

October 15, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade ↗

October 15, 2024

Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.

Via Investor's Business Daily

Key Takeaways From ADMA Biologics Analyst Ratings ↗

October 14, 2024

Via Benzinga

This Is What Whales Are Betting On ADMA Biologics ↗

October 10, 2024

Via Benzinga

IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns ↗

October 10, 2024

The company reiterated its outlook for 2024 and 2025.

Via Investor's Business Daily

Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits ↗

October 14, 2024

Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.

Via Investor's Business Daily

CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter ↗

October 11, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 10, 2024

Via Benzinga

Exploring high growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA). ↗

October 08, 2024

Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock.

Via Chartmill

Looking for growth without the hefty price tag? Consider NASDAQ:ADMA. ↗

September 24, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:ADMA.

Via Chartmill

In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics ↗

September 20, 2024

Via Benzinga

Assessing ADMA Biologics: Insights From 4 Financial Analysts ↗

August 12, 2024

Via Benzinga

ADMA Biologics Set to Join S&P SmallCap 600 Index

September 17, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference

September 10, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

What's Going On With ADMA Biologics Stock Monday? ↗

September 09, 2024

ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600.

Via Benzinga

Topics Stocks

Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗

September 09, 2024

Via Benzinga

Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark ↗

September 05, 2024

Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.

Via Investor's Business Daily

'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics ↗

August 30, 2024

"Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, there's some big money down the road."

Via Benzinga

Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers ↗

August 29, 2024

Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.

Via Investor's Business Daily

Biohaven Stock Earns Relative Strength Rating Upgrade ↗

August 21, 2024

Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.

Via Investor's Business Daily

SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗

August 21, 2024

A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance.

Via Investor's Business Daily

Immunome Stock Sees RS Rating Jump To 91 ↗

August 20, 2024

Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.

Via Investor's Business Daily

PTC Therapeutics Stock Earns RS Rating Upgrade To 83 ↗

August 19, 2024

The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

August 19, 2024

Via Benzinga

ADMA Biologics Announces Partial Paydown of Revolving Credit Facility

August 14, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? ↗

August 11, 2024

Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them?

Via Benzinga

Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday ↗

August 09, 2024

Via Benzinga

ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

ADMA stock results show that ADMA Biologics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update

August 08, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.